Get the Stockscreener App
71.24
0.15%
-0.11
After Hours:
71.24
Edwards Lifesciences Corp stock is traded at $71.24, with a volume of 5.44M.
It is down -0.15% in the last 24 hours and down -0.29% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$71.35
Open:
$71.46
24h Volume:
5.44M
Relative Volume:
1.23
Market Cap:
$41.95B
Revenue:
$5.72B
Net Income/Loss:
$4.17B
P/E Ratio:
10.22
EPS:
6.97
Net Cash Flow:
$259.90M
1W Performance:
+1.28%
1M Performance:
-0.29%
6M Performance:
+8.91%
1Y Performance:
-23.53%
1-Day Range:
$70.78
$72.29
1-Week Range:
$69.82
$72.29
52-Week Range:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
71.24 | 41.95B | 5.72B | 4.17B | 259.90M | 6.97 |
|
ABT
Abbott Laboratories
|
125.60 | 217.83B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.08 | 152.46B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
372.87 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.59 | 115.57B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock - Investing.com India
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock - Investing.com India
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock By Investing.com - Investing.com UK
Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group - Insider Monkey
Director Heisz Stone Sells Shares of Edwards Lifesciences Corp - GuruFocus.com
Edwards Lifesciences Corp. to Host Earnings Call - ACCESS Newswire
Jefferies maintains hold on Edwards Lifesciences stock, target $71 - Investing.com
Q2 EPS Forecast for Edwards Lifesciences Cut by Analyst - Defense World
Blood Pressure Monitor Market Growth USD 4.36 Billion by 2035 at a 6.1% of CAGR | Future Market Insights, Inc. - GlobeNewswire Inc.
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight - GuruFocus.com
Sabal Trust CO Has $2.23 Million Stake in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Oppenheimer & Co. Inc. Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Truist Financial Corp Buys 6,676 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Impax Asset Management Group plc Increases Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences CFO Scott Ullem sells $796k in stock - Investing.com
National Pension Service Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
HealthInvest Partners AB Buys 31,791 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
BankPlus Trust Department Takes $844,000 Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Union Bancaire Privee UBP SA Makes New $1.12 Million Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Hardman Johnston Global Advisors LLC Sells 7,170 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Private Advisor Group LLC Acquires 9,440 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Bank of New York Mellon Corp Has $1.34 Billion Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Catheter Market Global Report and Company Analysis 2025-2033 Featuring Abbott Laboratories, BD and Co, Boston Scientific, Teleflex, Medtronic, Johnson & Johnson, Edwards Lifesciences, Stryker - Yahoo Finance
A Look Into Edwards Lifesciences Inc's Price Over Earnings - Benzinga
W.G. Shaheen & Associates DBA Whitney & Co Increases Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference - BioSpace
What Will Edwards Lifesciences Reveal at Next Week's Major Healthcare Conference? - StockTitan
Edwards Sees ‘Emerging’ Opportunities in Structural Heart Disease - Orange County Business Journal
FRIDAY INVESTOR DEADLINE: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitEW - ACCESS Newswire
CIBC Asset Management Inc Sells 31,973 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Principal Financial Group Inc. Sells 23,591 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Pittenger & Anderson Inc. Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Baillie Gifford & Co. Buys 498,100 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Has $287,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Chevy Chase Trust Holdings LLC - MarketBeat
Rhumbline Advisers Sells 37,002 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WD Rutherford LLC Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Holdings Raised by Empower Advisory Group LLC - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):